A peptide derived from HIV's Vpr protein, injected directly into tumors, released tumor-specific antigens and triggered systemic anti-cancer immunity in mice.
Abscopal effect achievedIntratumoral Vpr peptide triggered immune responses against both local and distant tumors
What the researchers found
Intratumoral injection of a Vpr-derived peptide improved tumor immunogenicity by releasing whole-tumor antigens, eliciting systemic anti-tumor immune responses that targeted both local and distant tumors.
Why it matters
Traditional cancer vaccines require identifying specific tumor antigens, which is expensive and tumor-specific. This peptide-based approach turns the patient's own tumor into the vaccine source, potentially making cancer vaccination universally applicable without prior antigen identification.
The numbers in context
- 4 Vpr peptides designed; P1 and P4 showed cytotoxicity
- P1 induced apoptosis and immunogenic cell death (CRT, ATP, HMGB1)
- In situ P1 vaccination inhibited both local and distant tumors
- P1 + CD47 inhibitor enhanced distant tumor suppression
- Activated DCs, T cells, and macrophages
How the study worked
Animal study testing intratumoral injection of Vpr-derived peptides in tumor-bearing mice. Assessed local and systemic immune responses, tumor regression, and the abscopal effect on distant tumors.
Who was studied
Male C57BL/6 mice with bilateral MC38 (colon) and LLC (lung) subcutaneous tumors. In vitro cell line studies.
What this study cannot tell us
Animal study only — mouse immune systems differ significantly from human; the abscopal effect is notoriously difficult to reproduce clinically; safety of Vpr-derived peptides in humans needs evaluation; tumor heterogeneity may limit effectiveness.
How to read the evidence
Preclinical animal study demonstrating proof-of-concept. Promising but significant hurdles remain before human translation.
When this study was published
Published in 2025, reflecting cutting-edge peptide-based cancer immunotherapy research.
The bigger picture
In situ vaccination is a rapidly growing area of cancer immunotherapy. Using peptides to trigger antigen release from tumors represents an elegant intersection of peptide therapeutics and cancer immunology, potentially complementing checkpoint inhibitors and other immunotherapies.
Questions still open
- Would combining Vpr peptide injection with checkpoint inhibitors enhance the systemic anti-tumor response?
- Does the peptide's mechanism work across different tumor types and in immunologically 'cold' tumors?
- What is the safety profile of HIV-derived peptides in immunocompromised cancer patients?
Common questions
How can a virus-derived peptide fight cancer?
What is the abscopal effect?
Read the original research
In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity.
Vaccines, 13(7)
Citation
Pan, Danjie; Du, Ling; Liu, Jiayang; Kuerban, Kudelaidi; Huang, Xuan; Wang, Yue; Guo, Qiuyu; Chen, Huaning; Wang, Songna; Wang, Li; Zhou, Pinghong; Meng, Zhefeng; Ye, Li. (2025). In Situ Vaccination with a Vpr-Derived Peptide Elicits Systemic Antitumor Immunity by Improving Tumor Immunogenicity.. Vaccines, 13(7). https://doi.org/10.3390/vaccines13070710